Inovio appoints Scott White as vice president of clinical development in infectious diseases

18 March 2015

USA-based pharma company Inovio Pharmaceuticals (Nasdaq: INO) has appointed Scott White as vice president of clinical development in infectious diseases.

He will be responsible for advancing Inovio’s infectious disease portfolio of DNA immunotherapies and vaccines through clinical trials to commercialization. Dr White joins Inovio from GlaxoSmithKline (LSE: GSK) where he held positions of increasing responsibility leading global infectious disease clinical development programs.

Joseph Kim, president and chief executive of Inovio, said: "Scott will bring to Inovio his global experience and expert judgment in advancing infectious disease therapies and vaccines through numerous country regulatory agencies. As we ramp up clinical development of our rich pipeline, Inovio has now attracted three cancer and infectious disease opinion leaders this year. Their counsel as MDs will be invaluable to Inovio as we move our vaccines and immunotherapies closer to market."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK